About Us

Our history of innovation provides a taste

of the incredible future that awaits

 
2003

Company founded by Dov Tamarkin, PhD and Meir Eini

2006

License agreement for first product to reach the U.S. market through license with Bayer

2013

Phase 2 acne trial completed

2014

U.S. Management Team hired

IPO on Nasdaq

2015

Phase 1 Bridge/MUSE acne trial completed

2016

Phase 2 rosacea trial completed

2017

Initial phase 3 acne trials completed

 
2019

FMX103 NDA submitted

Long-term safety study in rosacea completed

Amzeeq approved